# SURTIME: HCP commentary report

> 34 HCP sources screened · 427 verified claims from 32 sources · 13 findings. Updated 2026-10-08.

## Report

- Trial: Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma
- NCT ID: NCT01099423
- Registry: https://clinicaltrials.gov/study/NCT01099423
- Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- Phase: Phase 3
- Status: Unknown
- Indications: Renal cell carcinoma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-08
- Last checked: 2026-10-08
- Release hash: 1953726f4d49fe979f722e8ee5e35737fb8e098a6c579d12e5992947a45c1ba3

## Counts

- HCP commentary sources screened: 34
- Sources cited by verified claims: 32
- Verified claims: 427
- Findings: 13
- People found in screened sources: 65
- People identity-verified: 53
- Voices cited: 38

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

SURTIME frames the question of whether patients whose kidney cancer has spread at diagnosis should have kidney surgery first or start systemic treatment before deciding on later surgery. Clinicians discuss trial endpoints and enrollment, patient selection by response and risk, surgical timing, residual renal lesions, postoperative therapy, and applicability to modern drug combinations. Further topics include local symptoms, operative risks, observation and radiation alternatives, biomarkers, treatment access, patient priorities and multidisciplinary care.

## Open Medical Affairs question

How can scientific exchange distinguish systemic-first sequencing for patients who need treatment from a blanket no-nephrectomy message?

## Findings (titles)

- F1. Systemic-first treatment is a selection strategy, not a universal prohibition on nephrectomy
- F2. Deferred nephrectomy has materially different timing interpretations
- F3. SURTIME is recalled as favorable, null or inconclusive, with substantial methodological caution
- F4. Selection extends beyond risk labels, with unresolved subgroup and histology boundaries
- F5. Residual renal lesions and treatment-free goals leave the later-surgery decision unresolved
- F6. Favorable observational signals provoke a dispute about causal interpretation
- F7. Symptoms and tumor thrombus are consequential exceptions, but not agreed automatic surgical indications
- F8. Perioperative management is more definite for TKIs than for immunotherapy, while surgical complexity remains debated
- F9. Modern systemic choices change the application of sunitinib-era sequencing evidence
- F10. Neither surgery nor immediate systemic treatment is inevitable for every metastatic presentation
- F11. Primary-tumor radiation remains a separate approach; later Cytoshrink commentary limits the earlier rationale
- F12. Biological explanations and biomarkers are attractive but remain hypotheses or research tools
- F13. Patient preferences, preparation and experienced multidisciplinary care are part of the decision itself

## Sample findings

### F3. SURTIME is recalled as favorable, null or inconclusive, with substantial methodological caution

A podcast speaker asked what limitations, apart from sample size, matter when interpreting SURTIME’s immediate-versus-deferred nephrectomy comparison in intermediate-risk, clear-cell metastatic renal cancer.

Source: podcast, 2024-02-18.

### F5. Residual renal lesions and treatment-free goals leave the later-surgery decision unresolved

A podcast speaker asked whether removing a residual kidney lesion makes sense when long-term TKI therapy might be stopped or paused because of side effects or patient choice. The speaker also asked about kidney-sparing surgery for a remaining cystic lesion after treatment.

Source: podcast, 2025-06-11.

## Trial aspects

| Aspect | Coverage | Claims | Sources |
| --- | --- | ---: | ---: |
| Immediate versus systemic-first nephrectomy | discussed | 13 | 7 |
| Outcome interpretation, endpoints and accrual | discussed | 17 | 7 |
| Selection by response and timing of consolidation | discussed | 18 | 5 |
| Risk scores, fitness, metastatic distribution and histology | discussed | 31 | 8 |
| Residual primary, renal preservation and postoperative treatment | discussed | 18 | 5 |
| Observational benefit, confounding and time-related bias | discussed | 25 | 10 |
| Local symptoms, thrombus and urgent-treatment exceptions | discussed | 11 | 3 |
| Perioperative holds, wound healing and operative complexity | discussed | 19 | 4 |
| Modern regimens, access, toxicity and surveillance alternatives | discussed | 32 | 9 |
| Primary-tumor radiation as an alternative cytoreductive approach | discussed | 33 | 3 |
| Mechanisms, biomarkers and tissue acquisition | discussed | 16 | 8 |
| Patient preference, preparation and multidisciplinary care | discussed | 18 | 7 |

## Cited sources by channel

- Podcasts: 10
- X threads: 21
- YouTube: 1

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus, give treatment advice.

- Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.
- For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- 11 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.
- 1 further source limit is recorded in the machine-readable scope of this record.
- The 34 retained commentary sources are not a count of independent HCPs and do not establish the prevalence of any view.
- Discussion located through trial identifiers and aliases may miss unnamed references or different transcription variants.
- One additional podcast could not be accessed; another transcript lacked additional audio verification, increasing uncertainty about exact wording.
- Several consequential panel views cannot be attributed to a named speaker. Rosters and nearby named comments do not resolve ownership.
- The full SURTIME publication text was unavailable. The supplied abstract nevertheless reports the null 28-week progression-free-rate result and a favorable nominal secondary intention-to-treat OS comparison; differing commentary remains attributed to each speaker rather than reconciled into one statistical assessment.
- Some relevant discussion of treatment stopping, systemic-regimen toxicity and cost, surgical exceptions, radiation-study access and support, and biomarker plans is not included in the available synthesis. The retained views should not be read as complete accounts of those decisions.
- Some social posts are truncated or omit outcome definitions, comparators and selection criteria. Their numerical summaries should not be treated as complete study reports.
- Cross-cancer, non-clear-cell, oligoprogressive and non-metastatic evidence appears only as explicitly limited context or alternatives; it does not establish effects in SURTIME's clinical population.
- The separate Cytoshrink commentary concerns early SBRT added to nivolumab/ipilimumab. Its null one-year PFS account, responder-only ongoing-response observation, intervention-arm imbalance and forthcoming OS/quality-of-life follow-up do not resolve nephrectomy sequencing.
- Source dates are publication or post dates unless the source explicitly supplies other timing; they do not prove a change of mind across discussions.

## Offer

- Size: Standard (32 commentary sources cited)
- Current edition: $1,250. Buy it below; a purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $2,200
- 6 months of weekly updates: $3,100
- 12 months of weekly updates: $4,400
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (53 now), at most $1,250; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/surtime-nct01099423
- Agents: POST https://www.erudio.com/api/orders with {"report": "surtime-nct01099423", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your licence key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Tom and Audun (invoice, PO, questions): https://www.erudio.com/contact?report=surtime-01099423

## Cite

Erudio Health. SURTIME (NCT01099423): HCP commentary report. Edition 1, v1.0.0. Accepted 2026-10-08. https://www.erudio.com/reports/surtime-nct01099423

## Machine access

- JSON: https://www.erudio.com/reports/surtime-nct01099423.json
- MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "surtime-01099423"}`